Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 59Carcinoma, Hepatocellular 46Colorectal Neoplasms 33Stomach Neoplasms 31Esophageal Squamous Cell Carcinoma 27Squamous Cell Carcinoma of Head and Neck 20Esophageal Neoplasms 14Small Cell Lung Carcinoma 13Neoplasm Metastasis 13Lung Neoplasms 13Rectal Neoplasms 12Head and Neck Neoplasms 12Advanced Solid Tumor 12Triple Negative Breast Neoplasms 11Cholangiocarcinoma 11Nasopharyngeal Carcinoma 10Melanoma 10Uterine Cervical Neoplasms 9Recurrence 9Neoplasms 9Colonic Neoplasms 9Pancreatic Neoplasms 7Urinary Bladder Neoplasms 6Solid Tumor 6Carcinoma, Transitional Cell 6Breast Neoplasms 6Sarcoma 5Lymphoma, Extranodal NK-T-Cell 5Lymphoma 5Hodgkin Disease 5

Interventions

Etoposide 3Carboplatin 2toripalimab 1tislelizumab 1fluzoparib 1atezolizumab 1Topotecan 1Temozolomide 1Radiotherapy 1PM 01183 1Drug Therapy 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
SCLC, Extensive Stage × tislelizumab × Clear all
NCT06793228 2025-01-27

Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia

Henan Cancer Hospital

Phase 2 Not yet recruiting
250 enrolled
Thoracic

SCLC, Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡